Results 71 to 80 of about 70,211 (203)

FoxO3a Drives the Metabolic Reprogramming in Tamoxifen-Resistant Breast Cancer Cells Restoring Tamoxifen Sensitivity

Cells, 2023
Tamoxifen-resistant breast cancer cells (TamR-BCCs) are characterized by an enhanced metabolic phenotype compared to tamoxifen-sensitive cells. FoxO3a is an important modulator of cell metabolism, and its deregulation has been involved in the acquisition of tamoxifen resistance.
Fiorillo M., Ricci E., Fava M., Longobucco C., Sotgia F., Rizza P., Lanzino M., Bonofiglio D., Conforti F. L., Catalano S., Barone I., Morelli C., Aquila S., Lisanti M. P., Sisci D.   +14 more
openaire   +3 more sources

PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer

Frontiers in Pharmacology, 2020
The M2 isoform of pyruvate kinase (PKM2), as a key glycolytic enzyme, plays important roles in tumorigenesis and chemotherapeutic drug resistance. However, the intricate mechanism of PKM2 as a protein kinase regulating breast cancer progression and ...
Pian Yu, Pian Yu, Ao-xue Li, Ao-xue Li, Xi-sha Chen, Xi-sha Chen, Min Tian, Min Tian, Hai-yan Wang, Xin-luan Wang, Yi Zhang, Kuan-song Wang, Yan Cheng, Yan Cheng   +13 more
doaj   +1 more source

Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer

Oncogenesis, 2021
Tamoxifen resistance remains a clinical problem in estrogen receptor (ER)-positive breast cancer. SUMOylation of ERα enhances ERα-induced transcription activity.
Runyi Ye, NiJiati AiErken, Xiaying Kuang, Huijuan Zeng, Nan Shao, Ying Lin, Pian Liu, Shenming Wang   +7 more
doaj   +1 more source

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. [PDF]

, 2019
Solid tumours are infiltrated by effector T cells with the potential to control or reject them, as well as by regulatory T (Treg) cells that restrict the function of effector T cells and thereby promote tumour growth1.
Cadilha, Bruno L, Carrizosa, Esteban, Di Pilato, Mauro, Kim, Edward Y, Ligorio, Matteo, Mani, Vinidhra, Marangoni, Francesco, Medoff, Benjamin D, Mempel, Thorsten R, Misale, Sandra, Nasrallah, Mazen N, Prüßmann, Jasper N, Seruggia, Davide, Usmani, Shariq M, Villani, Alexandra-Chloe, Warner, Ross D, Zappulli, Valentina   +16 more
core   +2 more sources

Identification of a putative protein-profile associating with tamoxifen therapy-resistance in breast cancer [PDF]

, 2009
Tamoxifen-resistance is a major cause of death in patients with recurrent breast cancer. Current clinical parameters can correctly predict therapy response in only half of the treated patients.
Bakker, M.A. (Michael) den, Foekens, J.A. (John), Jaitly, N. (Navdeep), Kang, H., Look, M.P. (Maxime), Martens, J.W.M. (John), Meijer van Gelder, M.E. (Marion), Paša-Tolić, L. (Ljiljana), Timmermans, A.M. (Mieke), Umar, A. (Arzu)   +9 more
core  

Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]

, 2015
BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T, Janku, Filip, Kurzrock, Razelle, Moulder, Stacy L, Stephens, Philip J, Wheler, Jennifer J, Yelensky, Roman   +6 more
core   +2 more sources

Chemotherapeutic effect of tamoxifen on temozolomide-resistant gliomas [PDF]

Anti-Cancer Drugs, 2015
Tamoxifen, a selective estrogen receptor modulator, is widely used in the chemotherapy of estrogen receptor-positive breast cancer. Recent studies have indicated that tamoxifen might have a potential chemotherapeutic effect on glioma. In the present study, we determined the chemotherapeutic action of tamoxifen on human glioma cell lines. Methylation of
Weiliang, He, Ran, Liu, Shao-Hua, Yang, Fang, Yuan   +3 more
openaire   +2 more sources

Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer

Cell Death and Disease, 2021
Selective estrogen receptor modulators (SERMs) such as tamoxifen have proven to be effective in the treatment of estrogen receptor (ER) positive breast cancer.
Wan-Xin Peng, Pratirodh Koirala, Huaixiang Zhou, Jiahong Jiang, Ziqiang Zhang, Liu Yang, Yin-Yuan Mo   +6 more
doaj   +1 more source

Alteration of AKT Activity Increases Chemotherapeutic Drug and Hormonal Resistance in Breast Cancer yet Confers an Achilles Heel by Sensitization to Targeted Therapy [PDF]

, 2008
The PI3K/PTEN/Akt/mTOR pathway plays critical roles in the regulation of cell growth. The effects of this pathway on drug resistance and cellular senescence of breast cancer cells has been a focus of our laboratory.
Adachi, Agostino Tafuri, Alberto M. Martelli, Allan, Andrzej Dzugaj, Aplin, Arcinas, Bader, Barnes, Blagosklonny, Blalock, Blalock, Brian D. Lehmann, Brooks, Brunet, Camilla Evangelisti, Cardone, Carpten, Carter, Centers for Disease Control and Prevention, Chang, Chang, Clark, Cocco, Coutant, Damen, Dan, David M. Terrian, Davies, Davis, Davis, DeGraffenried, del Peso, Delaney, Deng, Deng, Deng, Devarajan, Dijkers, Domina, Drexler, Du, Dufner, Eblen, Edinger, Ellis W.T. Wong, Elmore, Engleman, Enmark, Evangelisti, Fasco, Feilotter, Fingar, Flotho, Franca Stivala, Francesca Chiarini, Fry, Fu, Fuqua, Gao, Garcia, Gardai, Giles, Giovanni Ligresti, Gottlieb, Greenman, Hall-Jackson, Harada, Harada, Hay, Heimbrook, Hochhaus, Hollestelle, Howe, Howe, Hresko, Hu, Iijima, Inhorn, Jackson R. Taylor, James A. McCubrey, Jemal, Jia, Jin, Jonassen, Jörg Bäsecke, Kang, Karin, Kavanaugh, Kirkegaard, Konecny, Kornblau, Kristin M. Stadelman, Lanfrancone, Lange-Carter, Lawlor, Lee, Lee, Lehmann, Leslie, Lespagnard, Ley, Leygue, Li, Li, Li, Liang, Liaw, Linda S. Steelman, Lioubin, Lu, Luo, Lynch, Lyons, Ma, Madrid, Mahalingam, Mahimainathan, Manning, Marais, Marais, Marani, Marek Zarzycki, Martelli, Martelli, Martin, Mason, Massimo Libra, Matsuguchi, Mayo, Mayo, Mazzucchelli, McCubrey, McCubrey, McCubrey, Medema, Melissa L. Sokolosky, Michele Milella, Mobasheri, Mukherjee, Muraille, Myers, Nagata, Nakae, Navolanic, Negin Misaghian, Nimwegen, Noguchi, Obexer, Ohren, Okuda, Ozes, Panwalkar, Pao, Pao, Patrick M. Navolanic, Persad, Ponti, Poola, Poola, Qi, Raftopoulou, Rao, Rhei, Richard A. Franklin, Robinson, Rodriguez-Viciana, Romanelli, Romashkova, Samuels, Scheid, Sequist, Shaw, Shelton, Shelton, Shelton, Shelton, Shen, Shimada, Shishodia, Singh, Songyang, Sordella, Soule, Steck, Steelman, Steelman, Stefan Horn, Stephen L. Abrams, Stirewalt, Tai, Tamburini, Tamura, Tauchi, Taylor, Thomas, Tokunaga, Tokunaga, Tortora, Tresini, Troppmair, Trotman, Troussard, Tsutsui, Twiddy, Vogt, Wang, Wang, Wang, Wang, Weber, Wendel, Weng, Weng, Weston, William H. Chappell, Witzig, Xing, Xu, Xu, Yeh, Yoshida, You, Yu, Yu, Zhang, Zhou   +226 more
core   +1 more source

Tamoxifen resistance and adjuvant hormone therapy [PDF]

Breast Cancer Research, 2005
The Oxford Overview of adjuvant endocrine trials [1] indicates that 5 years of adjuvant tamoxifen reduces recurrence by 41% and deaths by 34% in women with oestrogen receptor (ER)-positive breast cancers. At 5 years, in all patients studied, the recurrence rate was 25.8% in controls but 13.9% on tamoxifen. There was a substantial 'carry over' effect of
openaire   +1 more source